Development and assessment of the efficacy and safety of human lung-targeting liposomal methylprednisolone crosslinked with nanobody
oleh: Dong Weng, Zhao-Fang Yin, Shan-Shan Chen, Xian He, Nan Li, Tao Chen, Hui Qiu, Meng-Meng Zhao, Qin Wu, Nian-Yu Zhou, Li-Qin Lu, Dan-Li Tang, Jia-Cui Song, Hui-Ping Li
| Format: | Article |
|---|---|
| Diterbitkan: | Taylor & Francis Group 2021-01-01 |
Deskripsi
Glucocorticoid (GC) hormone has been commonly used to treat systemic inflammation and immune disorders. However, the side effects associated with long-term use of high-dose GC hormone limit its clinical application seriously. GC hormone that can specifically target the lung might decrease the effective dosage and thus reduce GC-associated side effects. In this study, we successfully prepared human lung-targeting liposomal methylprednisolone crosslinked with nanobody (MPS-NSSLs-SPANb). Our findings indicate that MPS-NSSLs-SPANb may reduce the effective therapeutic dosage of MPS, achieve better efficacy, and reduce GC-associated side effects. In addition, MPS-NSSLs-SPANb showed higher efficacy and lower toxicity than conventional MPS.